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Table
Estimates and Relative Risks (RR) for 2-Year Relapse by Biomarker Strata Among All Patients
Biomarker Group All Patients PR Patients
N 2-Year Relapse
Estimate (95% CI)
P-value 2-Year RR for
Relapse (95% CI)
P-value N 2-Year Relapse
Estimate (95% CI)
P-value
IL-6 (pg/mL) < 2.15 18 11% (3-38%) 5 0%
 2.15 42 57% (42-72%) <0.01 7.11 (1.67-30.27) <0.01 19 59% (38-80%) 0.04
IL-10 (pg/mL) < 1.65 44 30% (19-47%) 17 30% (14-58%)
 1.65 16 75% (53-92%) <0.01 4.17 (1.88-9.29) <0.01 7 86% (54-99%) <0.01
sCD30(U/mL) < 8.65 39 32% (19-49%) 18 33% (17-60%)
 8.65 21 63% (43-82%) <0.01 2.88 (1.31-6.32) <0.01 6 100% 0.01
sIL-2R (U/mL) < 1276 52 37% (26-52%) 19 37% (20-63%)
1276 8 75% (44-96%) <0.01 3.38 (1.34-8.54) 0.01 5 80% (42-99%) 0.03
CCL17 (pg/mL) < 343.6 26 16% (6-36%) 8 13% (2-61%)
343.6 34 63% (47-79%) <0.01 6.10 (2.08-17.93) <0.01 16 63% (47-79%) 0.04
Galectin-1 (ng/mL) < 9.8 13 8% (1-43%) 3 0%
 9.8 47 52% (38-67%) <0.01 8.60 (1.16-63.54) 0.04 21 53% (34-75%) 0.14
CD68 (pg/mL) < 3.895 13 8% (1-43%) 5 0%
3.895 47 51% (38-67%) <0.01 8.53 (1.15-63.08) 0.04 19 59% (38-80%) 0.04
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S145Methods: Nine serum biomarkers (IL-6, IL-10, IL-13, sCD30,
sIL-2R, CCL17, Galectin-1, CD68 and CD163) selected for their
prognostic capacities in the upfront setting, were collected
pre-ASCT and measured in 61 patients undergoing trans-
plantation at the University of Minnesota or University of
Michigan. Using recursive partitioning methods, we calcu-
lated cutpoints for each biomarker to optimally separate
patients with early relapse (<2 years from ASCT) from those
with late relapse/complete remission (CR).
Results: The majority of patients (89%) were in CR (47%) or
partial remission (PR) (41%) at the time of transplant.
Twenty-six patients experienced early relapse following
ASCT, including 9 (31%) in CR and 12 (48%) in PR pre-ASCT.
Seven biomarkers identiﬁed patients with early relapse from
late relapse/CR (Table). By pre-ASCT disease status, no
biomarker distinguished early relapse among patients in CR
prior to transplantation. Six biomarkers identiﬁed early
relapse among patients in PR pre-ASCT.
Conclusions: Elevated serum biomarkers in cHL may identify
chemosensitive patients in pre-transplant PR at increased risk
for relapse. Identiﬁcation of these high-risk patients may offer
opportunities for intervention, such as alternative salvage
therapy pre-ASCT or post-ASCT maintenance therapy.168
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Introduction: Engraftment syndrome (ES) is a complication
of autologous hematopoietic progenitor cell transplantation
(AHPCT) characterized by fever, rash, pulmonary, liver, and/
or renal dysfunction. GM-CSF has been previously shown to
be associated with a higher risk of ES as compared to G-CSFafter AHPCT in heterogeneous patient cohort. We compared
the risk of ES with GM-CSF vs. G-CSF after AHPCT exclusively
in multiple myeloma (MM) patients who received the same
conditioning regimen.
Methods: We analyzed consecutive patients who received
melphalan 200 mg/m2 followed by an AHPCT for MM from
2008 to 2014. ES was diagnosed using a minor modiﬁcation
of the Maiolino criteria (MC) and Spitzer criteria (SC). ES
using MC was deﬁned as a noninfectious fever i 38C plus
rash or pulmonary inﬁltrates within 96 hours of neutrophil
recovery. ES using SC was deﬁned as the presence of 3 major
or 2 major plus 1 or more minor criteria within 96 hours of
neutrophil recovery (major criteria: noninfectious fever i
38C, rash, pulmonary inﬁltrates; minor criteria: liver/kidney
dysfunction, weight gain or encephalopathy). We analyzed
the incidence of ES using exact logistic regression, and time
to engraftment and hospital length of stay (LOS) using
Kaplan-Meier, logrank test and Cox proportional hazards
regression.
Results: A total of 111 patients were included (68 received
G-CSF and 43 received GM-CSF starting day +3 of AHPCT).
There was no signiﬁcant difference in patient age, gender
and race. Peripheral blood stem cell mobilization was ach-
ieved using a plerixafor-containing regimen in 45% of pa-
tients in the G-CSF group vs. 95% of patients in the GM-CSF
group (p¼0.001). A cyclophosphamide-containing regimen
was used for mobilization in 45% of patients in the G-CSF
group vs. 9% of patients in the GM-CSF group (p¼0.001). The
incidence of ES by MC and SC were 24% and 13%, respec-
tively. In unadjusted analysis, the GM-CSF group was
signiﬁcantly more likely to develop ES than the G-CSF group
using SC (28% vs. 3%; odds ratio, OR¼12.5; p¼0.001) and MC
(47% vs. 10%; OR¼7.42; p¼0.001). After adjusting for age,
gender, race and CD34+ cell dose, the GM-CSF group
remained at higher risk for ES than the G-CSF group
(OR¼10.4, p¼0.069 for SC; OR¼5.91, p¼0.029 for MC). The
GM-CSF group also had a signiﬁcantly longer time to
neutrophil engraftment than the G-CSF group by 1 day
(p¼0.001); the difference remained after multivariable
analysis (hazard ratio, HR¼0.22; 95% CI: 0.12 to 0.43;
p¼0.001). There was no signiﬁcant difference between the
two groups with respect to time to platelet engraftment
(p¼0.891). The median LOS of the G-CSF and GM-CSF group
was 15 and 16 days, respectively, although not statistically
signiﬁcant (p¼0.279).
BV Relapse HR vs. BSC
0.5 0.6 0.7 0.8
Life Years Gained 3.8 2.9 2.1 1.3
QALYs Gained 4.1 3.1 2.3 1.4
Additional Cost $155,000 $162,000 $169,000 $176,000
Cost Per Life Year
$6#Gained
$40,789 $55,862 $80,476 $135,384
Cost Per QALY Gained $37,804 $52,258 $73,478 $125,714
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S146Conclusion: GM-CSF use after AHPCT for MM may be
associated with a higher risk of ES and longer time to
neutrophil recovery as compared to G-CSF. Our observations
should prompt further investigation.
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: Hodgkin Lymphoma (HL) that relapses
following autologous stem cell transplant (ASCT) is costly to
treat and carries an unfavorable prognosis. Brentuximab
vedotin (BV), a novel agent to reduce the risk of relapse
following ASCT, offers the potential to be both effective and
cost-effective. Anticipating the results of the AETHERA trial,
we constructed a decision model to estimate the cost-effec-
tiveness of BV vs. best supportive care (BSC) for adult HL
patients at high risk of relapse following ASCT.
Methods, Intervention, & Analysis: The model is con-
structed as a Markov process, taking the U.S. health insurer
perspective and a lifetime horizon. Following ASCT, high-risk
HL patients are treatedwith BV or BSC alone. After treatment,
patients enter one of 5 health states: remission; relapse/
salvage therapy; relapse/palliative care; 2nd remission;death. Transition probabilities were based on published re-
ports, bone marrow transplant registry data, and life tables.
Drug cost was ASP + 6%. Costs are based on 2013 Medicare
reimbursements.
Findings & Interpretation: In the base case (HR 0.667 for BV
vs. BSC), total life years, QALYs, and costs were 16.7, 13.4, and
$308,000 for the BV strategy vs. 14.3, 10.9, and $140,000 for
the BSC strategy. The cost per life year gained and cost per
QALY gained for BV vs. BSC were $70,000 and $67,200,
respectively. Economic outcomes across a range of hazard
ratios (HR) for BV vs BSC are as follows:
Results were most sensitive to: (a) efﬁcacy of BV (relapse
HR), (b) monthly drug cost, and (3) cycles of treatment. In the
base case, the likelihood of BV being cost-effective was 92.6%
at a willingness to pay threshold of $100,000 per QALY.
Discussion & Implications: BV has the potential to be cost-
effective in HL patients at risk for relapse following ASCT. The
AETHERA trial will provide more precise estimates of the
cost-effectiveness of this therapy.
